Biogen | BIIB - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
ALKERMES USD 331.33M 7M 2026-03
Amgen USD 6.89B 415M 2025-12
Bayer EUR 6.94B 1.58B 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
Incyte USD 1.17B 217.51M 2026-03
Merck USD 10.85B 2.57B 2025-12
Moderna USD -566M 792M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 10.07B 184M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Sanofi EUR 8.11B 343M 2026-03
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
United Therapeutics USD 315.5M 286.6M 2025-12
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03